To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Plasma N-glycans in color… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Plasma N-glycans in colorectal cancer risk

Journal article
Authors M. Doherty
E. Theodoratou
I. Walsh
Barbara Adamczyk
H. Stockmann
F. Agakov
M. Timofeeva
I. Trbojevic-Akmacic
F. Vuckovic
F. Duffy
C. A. McManus
S. M. Farrington
M. G. Dunlop
M. Perola
G. Lauc
H. Campbell
P. M. Rudd
Published in Scientific Reports
Volume 8
ISSN 2045-2322
Publication year 2018
Published at Institute of Biomedicine, Department of Medical Biochemistry and Cell Biology
Language en
Keywords ovarian-cancer, acetylglucosaminyltransferase v, structural, requirements, glycoprofiling platform, serum glycoproteins, glycosylation, igg, disease, glycome, arthritis, Science & Technology - Other Topics
Subject categories Cancer and Oncology, Medical cell biology


Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma W-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, W-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?